SCOLR Pharma Extends Research Agreement with Consumer Products Company
News Dec 07, 2007
SCOLR Pharma, Inc. has announced an extension of its research agreement with a global consumer products company to co-develop an application of its CDT® drug delivery technology.
Stephen J. Turner, SCOLR’s Vice President and Chief Technical Officer, stated “This extension is a positive indication of the progress we are making with our co-development partner on a novel application of our CDT drug delivery technology. We remain optimistic that if successful, a branded consumer product incorporating our technology could begin commercialization by 2009.”
SCOLR recently announced entering a development and licensing agreement with Dr. Reddy for a cardiopulmonary application of its CDT technology. SCOLR also continues its collaboration with Biocryst to development of an oral application of Biocryst’s peramivir, an anti-viral compound currently in clinical trials as potential intramuscular and intervenous treatments for seasonal and life-threatening influenza.
Under the terms of the agreement, SCOLR will receive a research fee. If the program is successful, it is anticipated that the parties would enter a global license agreement to allow for application of SCOLR’s technology.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018